Arthritis News - 1999
Immunex
Corporation and Wyeth-Ayerst Pharmaceuticals recently announced that the
U.S. Food and Drug Administration (FDA) has approved Enbrel for the treatment
of moderately to severely active polyarticular-course juvenile rheumatoid
arthritis (JRA) in patients with inadequate response to one or more disease
modifying medicines. JRA affects children before the age of sixteen and
can cause deformity, joint pain, stunted growth and increased mortality.
(see Clinical Classification
Criteria for JRA)